Peptides by goal · Weight, muscle and energy

Peptides for weight loss, ranked by evidence

Checked against our library and study pagesPublished by PepVault

Of the 31 compounds in our library linked to weight loss, 23 have been studied in people for it (6 FDA-approved for a related use), 4 have animal or lab evidence only, and 4 rest on community reports alone. Semaglutide ranks first, with 17 of our study pages in people on weight loss.

Peptides and weight loss

Weight loss is where most people first meet peptides, and it is the goal with by far the most human research behind it. The drugs that copy gut hormones such as GLP-1 have large trials with thousands of people; most of the other peptides sold for fat loss have been tested in mice or rats, or not at all.

For weight loss, the size and length of the trials matter most: a result in a year-long trial with hundreds of people counts for far more than a short study in mice. Side effects such as nausea, and what happens to the weight after stopping, are part of the picture too.

The evidence ladder for weight loss: FDA-approved 6, Human studies 17, Animal or lab 4, Reports only 4, of 31 compounds.FDA-approved6Human studies17Animal or lab4Reports only4
How many of the 31 compounds on this page reach each rung, strongest evidence at the top.
A smiling woman in a dark training top in her kitchen, holding a glass of water

Model. Individual results vary.

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

The 31 compounds, ranked by evidence

FDA-approved for a related use

6 compounds

  1. Semaglutide

    #1 · FDA-approved

    A GLP-1 receptor agonist that mimics a gut hormone your body releases after eating: it reduces appetite and slows stomach emptying. Commonly reported: the constant background thoughts about food ("food noise") go quiet and portions shrink without effort, with nausea worst in the first days after each dose step. For weight loss it sits on the top rung: the library records an FDA approval for a related use, and 17 of our study pages in people cover it.

    From its library entry: “FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial.”

    What FDA approved it for, from the labels (read Nov 18, 2026): Ozempic (injection) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack, stroke and kidney decline in those with heart or kidney disease; Rybelsus (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk; Wegovy (injection) for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and a fatty-liver disease (MASH) with moderate to advanced scarring; Wegovy (tablet) for weight loss and keeping it off, and lowering heart risk in adults with heart disease and excess weight; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus). Semaglutide: legal and regulatory status

    Semaglutide: 11.85% more weight loss than placebo without diabetesOur study page: meta-analysis in people, 3,613 people, 2022

    Why it is here: its library entry lists “Appetite control” and “Weight loss” and 18 of our study pages are about this goal.

  2. Tirzepatide

    #2 · FDA-approved

    The first dual GIP/GLP-1 receptor agonist: it activates two gut-hormone pathways at once, and in a head-to-head trial it produced more weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). Commonly reported: very strong appetite suppression and meals ending early, with nausea or tiredness for a day or two after the injection, mostly after dose increases. For weight loss it sits on the top rung: the library records an FDA approval for a related use, and 6 of our study pages in people cover it.

    From its library entry: “FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound).”

    What FDA approved it for, from the labels (read Nov 18, 2026): Mounjaro (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes; Zepbound (injection) for weight loss and keeping it off, and moderate to severe obstructive sleep apnea in adults with obesity. Tirzepatide: legal and regulatory status

    Tirzepatide: up to 20.9% weight loss at 72 weeks in SURMOUNT-1Our study page: randomized trial in people, 2,539 people, 2022

    Why it is here: its library entry lists “Superior weight loss” and “Appetite control” and 7 of our study pages are about this goal.

  3. Tesamorelin

    #3 · FDA-approved

    The only GHRH analog currently FDA-approved (to reduce excess abdominal fat in HIV lipodystrophy). Tesamorelin targets visceral fat, the deep abdominal fat around the organs: in two phase 3 trials it cut visceral fat about 15% in 26 weeks. For weight loss it sits on the top rung: the library records an FDA approval for a related use, and 5 of our study pages in people cover it.

    What FDA approved it for, from the labels (read Nov 18, 2026): Egrifta (injection) for reducing excess belly fat in adults with HIV and lipodystrophy (its label says it is not for weight loss). Tesamorelin: legal and regulatory status

    Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyOur study page: meta-analysis in people, 2026

    Why it is here: its library entry lists “Visceral fat loss” and 5 of our study pages are about this goal.

  4. Setmelanotide

    #4 · FDA-approved

    A daily shot (Imcivree) for rare kinds of obesity in which the brain's fullness signal is broken: after damage to the hypothalamus, in Bardet-Biedl syndrome, or with a POMC, PCSK1 or LEPR gene variant. In those people it cuts hunger and weight, by about 16% of BMI in a year in its 2026 hypothalamic-obesity trial, but the label says it is not expected to work in common obesity. For weight loss it sits on the top rung: the library records an FDA approval for a related use, and 4 of our study pages in people cover it.

    From its library entry: “FDA-approved in 2020; acquired hypothalamic obesity was added in March 2026.”

    What FDA approved it for, from the labels (read Nov 18, 2026): Imcivree (injection) for reducing excess weight and keeping it off in rare kinds of obesity: acquired hypothalamic obesity (age 4 and older), and Bardet-Biedl syndrome or a confirmed POMC, PCSK1 or LEPR gene deficiency (age 2 and older). Setmelanotide: legal and regulatory status

    Setmelanotide: 16.5% BMI drop at 52 weeks in hypothalamic obesityOur study page: randomized trial in people, 120 people, 2026

    Why it is here: its library entry lists “Weight loss” and 4 of our study pages are about this goal.

  5. Orforglipron

    #5 · FDA-approved

    A GLP-1 drug in a once-daily tablet that is not a peptide, so it comes with no fasting or water rules: Lilly's Foundayo, FDA-approved in April 2026 for weight management. Its top dose averaged about 11% weight loss at 72 weeks in its main trial. For weight loss it sits on the top rung: the library records an FDA approval for a related use, and 2 of our study pages in people cover it.

    From its library entry: “FDA-approved on April 1, 2026, as Foundayo for chronic weight management.”

    What FDA approved it for, from the labels (read Nov 18, 2026): Foundayo (tablet) for weight loss and keeping it off, in adults with obesity or with excess weight and a weight-related condition. Orforglipron: legal and regulatory status

    Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1Our study page: randomized trial in people, 3,127 people, 2025

    Why it is here: its library entry lists “Weight loss” and “Appetite control” and 2 of our study pages are about this goal.

  6. Liraglutide

    #6 · FDA-approved

    The predecessor to semaglutide: a GLP-1 receptor agonist that reduces appetite and improves blood sugar control, given as a daily injection rather than weekly. For weight loss it sits on the top rung: the library records an FDA approval for a related use, and 1 of our study pages in people covers it.

    From its library entry: “FDA-approved for diabetes (Victoza) and obesity (Saxenda), with one of the longest track records of any GLP-1 drug.”

    What FDA approved it for, from the labels (read Nov 18, 2026): Victoza (injection) for blood sugar control in type 2 diabetes (adults and children 10 and older), and lowering heart risk in adults with type 2 diabetes and heart disease; Saxenda (injection) for weight loss and keeping it off, in adults and in children 12 and older with obesity. Liraglutide: legal and regulatory status

    Liraglutide: 6.4% weight loss vs 15.8% on semaglutide in STEP 8Our study page: randomized trial in people, 338 people, 2022

    Why it is here: its library entry lists “Appetite control” and “Weight loss” and 1 of our study pages is about this goal.

Studied in people

17 compounds

  1. Retatrutide

    #7 · Human studies

    The first triple agonist to reach phase 3: it activates GLP-1, GIP and glucagon receptors at once, and the glucagon arm adds extra calorie burn (shown in mice). Commonly reported: appetite suppression even stronger than tirzepatide, GI side effects after each step-up, and a higher resting heart rate. For weight loss it has been studied in people: 5 of our study pages in people are about it, beside 2 animal or lab studies (mice and hamsters).

    Retatrutide: top odds of 15% or more weight loss across 19 trialsOur study page: meta-analysis in people, 29,506 people, 2025

    Why it is here: its library entry lists “Highest weight loss” and “Appetite control” and 7 of our study pages are about this goal.

  2. Cagrilintide

    #8 · Human studies

    A long-acting version of amylin, the fullness hormone the pancreas releases alongside insulin, given as a weekly shot. On its own, its higher doses led to about 10–12% weight loss in trials; the crowd mostly runs it beside a GLP-1 such as semaglutide, tirzepatide or retatrutide, the way Novo Nordisk pairs it with semaglutide in CagriSema. For weight loss it has been studied in people: 5 of our study pages in people are about it.

    Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1Our study page: randomized trial in people, 3,417 people, 2025

    Why it is here: its library entry lists “Satiety” and “Weight loss” and 5 of our study pages are about this goal.

  3. Survodutide

    #9 · Human studies

    A weekly shot that activates two receptors: GLP-1, for appetite and blood sugar, and glucagon, which clears fat from the liver and, in mice, raises energy use. Commonly reported: less appetite and early fullness, with nausea or vomiting during the long dose climb and a resting heart rate a few beats higher. For weight loss it has been studied in people: 3 of our study pages in people are about it, beside 1 animal or lab study (mice).

    Survodutide: up to 13.0% weight loss at 76 weeks in SYNCHRONIZE-1Our study page: randomized trial in people, 725 people, 2026

    Why it is here: its library entry lists “Weight loss” and “Appetite control” and 4 of our study pages are about this goal.

  4. Pramlintide

    #10 · Human studies

    The first amylin drug (Symlin), approved in 2005 for people with diabetes who use mealtime insulin: a shot before each main meal that slows digestion and makes people feel full sooner. In its diabetes trials weight fell about 1 to 2 kg, and in obesity trials without insulin, weight loss of about 6 to 7 kg beyond placebo was seen at a year. For weight loss it has been studied in people: 3 of our study pages in people are about it.

    Pramlintide: weight loss maintained over 12 months in obesityOur study page: randomized trial in people, 411 people, 2008

    Why it is here: its library entry lists “Appetite control” and 3 of our study pages are about this goal.

  5. CagriSema

    #11 · Human studies

    Two weekly drugs in one regimen: cagrilintide, a long-acting version of the fullness hormone amylin, and semaglutide, the GLP-1 drug in Wegovy and Ozempic. Amylin and GLP-1 curb appetite through partly different routes, so together they go further than either alone; Novo Nordisk filed it for FDA approval in December 2025. For weight loss it has been studied in people: 2 of our study pages in people are about it.

    CagriSema: 13.7% weight loss at 68 weeks in REDEFINE 2Our study page: randomized trial in people, 1,206 people, 2025

    Why it is here: its library entry lists “Weight loss” and “Appetite control” and 2 of our study pages are about this goal.

  6. Mazdutide

    #12 · Human studies

    A once-weekly GLP-1 and glucagon dual agonist from Innovent and Eli Lilly, approved in China in 2025 for weight management (as Xinermei) and type 2 diabetes; it is not FDA-approved. Commonly reported: strong appetite suppression and GI side effects after each step-up, much as with other weekly GLP-1s; user reports from outside China are still few. For weight loss it has been studied in people: 2 of our study pages in people are about it.

    Mazdutide: 14.01% weight loss at 48 weeks in GLORY-1 (6 mg arm)Our study page: randomized trial in people, 610 people, 2025

    Why it is here: its library entry lists “Weight loss” and “Appetite control” and 2 of our study pages are about this goal.

  7. Semaglutide (oral)

    #13 · Human studies

    Semaglutide as a daily tablet instead of a weekly shot, FDA-approved as Rybelsus (3, 7 and 14 mg) and Ozempic tablets (1.5, 4 and 9 mg) for type 2 diabetes and as Wegovy tablets (up to 25 mg) for weight management. For weight loss it has been studied in people: 2 of our study pages in people are about it.

    Semaglutide pill: 15.1% weight loss at 68 weeks in OASIS 1Our study page: randomized trial in people, 667 people, 2023

    Why it is here: 2 of our study pages are about this goal.

  8. Eloralintide

    #14 · Human studies

    A once-weekly amylin drug from Eli Lilly, built to copy the fullness hormone the pancreas releases with insulin, and to act on its receptor more selectively than cagrilintide does. Commonly reported: in trials, fewer cravings, especially for sugar, and less food noise, with nausea and tiredness more likely on the higher doses. For weight loss it has been studied in people: 2 of our study pages in people are about it.

    Eloralintide: 2.6% to 11.3% weight loss at 12 weeks in phase 1Our study page: randomized trial in people, 100 people, 2026

    Why it is here: its library entry lists “Weight loss” and “Satiety” and 2 of our study pages are about this goal.

  9. Ecnoglutide

    #15 · Human studies

    A weekly GLP-1 drug from Sciwind Biosciences, approved in China in 2026 for weight management and type 2 diabetes, and the first approved GLP-1 drug built to be "cAMP-biased". Commonly reported: appetite control and early GI side effects, much as with semaglutide. For weight loss it has been studied in people: 1 of our study pages in people is about it.

    Ecnoglutide: 13.2% weight loss at 40 weeks in the 2.4 mg armOur study page: randomized trial in people, 664 people, 2025

    Why it is here: its library entry lists “Weight loss” and 1 of our study pages is about this goal.

  10. Amycretin

    #16 · Human studies

    One peptide from Novo Nordisk that gives both the GLP-1 and the amylin signal, the pair CagriSema delivers as two drugs, as a weekly shot or a daily tablet. Commonly reported: in trials, strong appetite loss and GI side effects during the step-ups. For weight loss it has been studied in people: 1 of our study pages in people is about it, beside 1 animal or lab study (mice and rats).

    Amycretin: 24.3% weight loss at 36 weeks in a phase 1b/2a trialOur study page: randomized trial in people, 125 people, 2025

    Why it is here: its library entry lists “Weight loss” and “Satiety” and 2 of our study pages are about this goal.

  11. Efinopegdutide

    #17 · Human studies

    A once-weekly GLP-1 and glucagon dual agonist that Merck is developing for MASH, the inflamed form of fatty liver disease. Commonly reported: GI side effects during step-ups, and weight loss too. For weight loss it has been studied in people: 1 of our study pages in people is about it.

    Efinopegdutide: up to 7.2% more weight loss than placebo at 12 weeksOur study page: randomized trial in people, 195 people, 2021

    Why it is here: its library entry lists “Weight loss” and 1 of our study pages is about this goal.

  12. Enicepatide

    #18 · Human studies

    A weekly GLP-1 and GIP dual agonist from Roche, the same two receptors as tirzepatide, built to keep the receptors responsive by avoiding one of their shut-off signals. Commonly reported: appetite dropping in the first days. For weight loss it has been studied in people: 1 of our study pages in people is about it.

    Enicepatide: -4.7% to -8.0% body weight change by day 29 in phase 1Our study page: randomized trial in people, 2026

    Why it is here: its library entry lists “Weight loss” and 1 of our study pages is about this goal.

  13. Oxytocin

    #19 · Human studies

    Best known as the "bonding hormone," oxytocin is a hypothalamic neuropeptide with broader effects than most people realize. Hypothalamic neuropeptide with broad effects: single nasal doses cut food intake at a test meal and blunted stress responses in small studies, though an 8-week trial produced no weight loss. For weight loss it has been studied in people: 1 of our study pages in people is about it.

    Oxytocin nasal spray cut calories eaten at a breakfast test in menOur study page: randomized trial in people, 25 people, 2015

    Why it is here: its library entry lists “Appetite control” and 1 of our study pages is about this goal.

  14. Petrelintide

    #20 · Human studies

    A once-weekly amylin drug from Zealand Pharma and Roche, a long-acting copy of the fullness hormone the pancreas releases with insulin. In its 42-week phase 2 trial, people lost about 8% to 10% of their weight at 28 weeks and up to about 10.7% by week 42, less than GLP-1 drugs but with GI side effects close to placebo apart from mild nausea. For weight loss it has been studied in people: 1 of our study pages in people is about it.

    Petrelintide: up to 8.6% weight loss at 16 weeks in phase 1Our study page: randomized trial in people, 2026

    Why it is here: its library entry lists “Weight loss” and “Satiety” and 1 of our study pages is about this goal.

  15. VK2735

    #21 · Human studies

    A weekly GLP-1 and GIP dual agonist from Viking Therapeutics, the same two-receptor approach as tirzepatide, also being tested as a daily tablet. In its 13-week phase 2 trial, people lost about 9% to 15% of their body weight depending on the dose, with no sign of levelling off. For weight loss it has been studied in people: 1 of our study pages in people is about it.

    VK2735: up to 14.7% weight loss at 13 weeks in VENTUREOur study page: randomized trial in people, 2026

    Why it is here: its library entry lists “Weight loss” and “Appetite control” and 1 of our study pages is about this goal.

  16. AOD-9604

    #22 · Human studies

    A modified fragment of human growth hormone that targets fat metabolism. In rodents it boosted the breakdown of stored fat and blocked new fat formation, without affecting blood sugar or IGF-1. For weight loss the trials in people that its library entry cites put it on this rung; our 1 study page on it for this goal is an animal or lab study (mice).

    The library’s research note “What AOD-9604 is built on” rests on studies in people.

    AOD-9604 lowered body weight and body fat in obese mice over 14 daysOur study page: animal study in mice, 2001

    Why it is here: its library entry lists “Fat metabolism” and 1 of our study pages is about this goal.

  17. Pemvidutide

    #23 · Human studies

    An investigational once-weekly GLP-1 and glucagon dual agonist from Altimmune, built for a gentler start: its two lower doses were given from the first injection without a dose ramp. The GLP-1 arm curbs appetite; the glucagon arm acts directly on the liver, where it raises fat burning and curbs fat-making, and its developer now runs it mainly for liver disease. For weight loss the trials in people that its library entry cites put it on this rung; our 1 study page on it for this goal is an animal or lab study (mice).

    The library’s research note “Liver fat drops faster than weight” rests on studies in people.

    Pemvidutide cut body weight about 25% in mice with NASHOur study page: animal study in mice, 2022

    Why it is here: its library entry lists “Weight loss” and 1 of our study pages is about this goal.

Animal or lab studies only

4 compounds

  1. Fragment 176-191

    #24 · Animal or lab

    A stabilized fragment of the growth hormone molecule (amino acids 176-191), usually sold as the same peptide as AOD-9604. It targets fat cells: in rodents it boosted fat breakdown without affecting blood sugar or IGF-1. For weight loss the evidence its library entry cites is from animal studies, and none of our study pages covers it yet.

    The library’s research note “What Fragment 176-191 is built on” rests on animal studies.

    Why it is here: its library entry lists “Targeted fat loss”.

  2. Humanin

    #25 · Animal or lab

    Another mitochondrial-derived peptide. For weight loss the evidence is from animals or cells only: 1 study page of ours, in mice.

    MOTS-c prevented diet-induced obesity and insulin resistance in miceOur study page: animal study in mice, 2015

    Why it is here: 1 of our study pages is about this goal.

  3. MOTS-c

    #26 · Animal or lab

    A peptide encoded by your mitochondrial DNA, the energy-producing organelles inside every cell. Two different axes of metabolic health: GLP-1 drugs work on appetite and insulin from the brain-gut side, while MOTS-c works at the mitochondrial level. For weight loss the evidence is from animals or cells only: 1 study page of ours, in mice.

    MOTS-c prevented diet-induced obesity and insulin resistance in miceOur study page: animal study in mice, 2015

    Why it is here: 1 of our study pages is about this goal.

  4. SLU-PP-332

    #27 · Animal or lab

    An experimental "exercise mimetic": a small molecule (not a peptide) from a St. Louis-based academic team that switches on the ERR receptors behind mitochondria and endurance. In mice it lengthened treadmill runs by about 70% and cut fat gain without changing food intake, but it has never been tested in people, and its developers report it lacks oral bioavailability, so what a capsule delivers is unknown. For weight loss the evidence is from animals or cells only: 1 study page of ours, in mice.

    SLU-PP-332 cut fat mass and improved insulin sensitivity in obese miceOur study page: animal study in mice, 2024

    Why it is here: its library entry lists “Fat metabolism” and 1 of our study pages is about this goal.

Community reports only

4 compounds

  1. HGH

    #28 · Reports only

    Recombinant human growth hormone — an identical copy of the GH your pituitary makes. It stimulates IGF-1 production, fat burning, muscle protein synthesis and tissue repair. For weight loss it rests on community reports: no study page of ours covers this goal, and the library lists it under “Fat loss”.

    Why it is here: its library entry lists “Fat loss”.

  2. CJC-1295 no DAC

    #29 · Reports only

    The shorter-acting version of CJC-1295, meant to give sharp, pulse-like GH release. Commonly reported in weeks 4 to 8: visible body-composition changes, more lean mass and modest fat loss, with sleep strong and consistent. For weight loss it rests on community reports: no study page of ours covers this goal, and the library lists it under “Fat loss”.

    Why it is here: its library entry lists “Fat loss”.

  3. 5-Amino-1MQ

    #30 · Reports only

    A small molecule (not a peptide) that blocks the NNMT enzyme in fat cells, which raises NAD+ and pushes fat cells toward burning energy. In obese mice it reduced weight and fat without cutting food intake. For weight loss it rests on community reports: no study page of ours covers this goal, and the library lists it under “Fat metabolism”.

    Why it is here: its library entry lists “Fat metabolism”.

  4. Melanotan II

    #31 · Reports only

    A broad-spectrum melanocortin agonist originally developed for sunless tanning. MT-2 stimulates melanocytes to produce melanin (it works without sun; UV exposure speeds and deepens the tan), increases libido through central nervous system pathways, and can reduce appetite. For weight loss it rests on community reports: no study page of ours covers this goal, and the library lists it under “Appetite suppression”.

    Why it is here: its library entry lists “Appetite suppression”.

How they differ

Route, dosing frequency and half-life as each library entry records them, for the 31 compounds in ranked order.

CompoundEvidenceRouteDosing frequencyHalf-life
SemaglutideFDA-approvedSubQ injectionWeekly SubQ~1 week
TirzepatideFDA-approvedSubQ injectionWeekly~5 days
TesamorelinFDA-approvedSubQ injectionDaily~8–11 min
SetmelanotideFDA-approvedSubQ injectionDaily SubQ~11 hours
OrforglipronFDA-approvedOral tabletDaily~29–49 hours
LiraglutideFDA-approvedSubQ injectionDaily SubQ~13 hours
RetatrutideHuman studiesSubQ injectionWeekly~6 days
CagrilintideHuman studiesSubQ injectionWeekly~1 week
SurvodutideHuman studiesSubQ injectionWeeklyLong enough for once-weekly dosing: a fatty-acid chain binds it to albumin
PramlintideHuman studiesSubQ injection2–3x daily SubQ, right before major meals~0.8 hours
CagriSemaHuman studiesSubQ injectionWeekly~1 week for each component
MazdutideHuman studiesSubQ injectionWeekly~10 days
Semaglutide (oral)Human studiesOral tabletDaily~1 week
EloralintideHuman studiesSubQ injectionWeekly~14 days
EcnoglutideHuman studiesSubQ injectionWeekly~5.5 days
AmycretinHuman studiesSubQ injectionWeekly~88 hours
EfinopegdutideHuman studiesSubQ injectionWeeklyNot reported in an open human PK source
EnicepatideHuman studiesSubQ injectionWeekly~5.5 days
OxytocinHuman studiesIntranasal1–2x daily or as needed~1–6 min
PetrelintideHuman studiesSubQ injectionWeekly~10 days
VK2735Human studiesSubQ injectionWeekly~9 days
AOD-9604Human studiesSubQ injectionDaily, fasted~30 min
PemvidutideHuman studiesSubQ injectionWeeklyNot published: built for weekly dosing
Fragment 176-191Animal or labSubQ injectionDaily, split into 2 doses, fasted~30 min
HumaninAnimal or labSubQ injectionWeeklyUnknown in humans
MOTS-cAnimal or labSubQ injection, IM injection2–3× weeklyHours
SLU-PP-332Animal or labOral capsuleDailyUnknown: never measured in people
HGHReports onlySubQ injectionDaily SubQ injection.~3-4 hours
CJC-1295 no DACReports onlySubQ injection2–3x daily~30 min
5-Amino-1MQReports onlyOralDailyUnknown
Melanotan IIReports onlySubQ injectionLoading: 250mcg daily for 1-2 weeks. Maintenance: 250-500mcg 2-3x/week or as needed.Unknown in humans

Compared side by side

Guides

Questions

Which peptides have been studied in people for weight loss?

23 of the 31 on this page: Semaglutide, Tirzepatide, Tesamorelin, Setmelanotide, Orforglipron, Liraglutide, Retatrutide, Cagrilintide, Survodutide, Pramlintide, CagriSema, Mazdutide, Semaglutide (oral), Eloralintide, Ecnoglutide, Amycretin, Efinopegdutide, Enicepatide, Oxytocin, Petrelintide, VK2735, AOD-9604 and Pemvidutide. The rest have animal or lab evidence or community reports only.

Is any peptide FDA-approved for weight loss?

Semaglutide, Tirzepatide, Tesamorelin, Setmelanotide, Orforglipron and Liraglutide: the library records an FDA approval for a related use (Semaglutide: FDA-approved for type 2 diabetes, weight management, heart-risk reduction and MASH, with about 15% average weight loss at 68 weeks in its main trial; Tirzepatide: FDA-approved for diabetes (Mounjaro) and for weight management and sleep apnea (Zepbound); Tesamorelin: The only GHRH analog currently FDA-approved (to reduce excess abdominal fat in HIV lipodystrophy); Setmelanotide: FDA-approved in 2020; acquired hypothalamic obesity was added in March 2026; Orforglipron: FDA-approved on April 1, 2026, as Foundayo for chronic weight management; Liraglutide: FDA-approved for diabetes (Victoza) and obesity (Saxenda), with one of the longest track records of any GLP-1 drug).

Which is the best-studied peptide for weight loss?

By our count, Semaglutide, with 17 study pages in people about weight loss, the most of any compound here.

Which ones have only animal or lab evidence for weight loss?

4 compounds: Fragment 176-191, Humanin (mice), MOTS-c (mice) and SLU-PP-332 (mice). A result in animals or cells often doesn’t hold in people.

How are the peptides for weight loss taken?

Of the 31 compounds for weight loss, 26 are taken by injection, 4 by mouth, 1 as a nasal spray, as their library entries list (some have more than one route). The table above gives each one’s route, how often it is dosed and its half-life.

How do the peptides for weight loss compare with each other?

We compare 40 pairs of them side by side: Retatrutide vs Tirzepatide, Semaglutide vs Tirzepatide, Retatrutide vs Semaglutide, Mazdutide vs Tirzepatide, Survodutide vs Retatrutide, Orforglipron vs Semaglutide, Cagrilintide vs Semaglutide, Liraglutide vs Semaglutide, Tirzepatide vs Liraglutide, Semaglutide vs Semaglutide (oral), Orforglipron vs Tirzepatide, Orforglipron vs Semaglutide (oral), Retatrutide vs Orforglipron, Retatrutide vs Mazdutide, Mazdutide vs Survodutide, Retatrutide vs Cagrilintide, Tirzepatide vs Cagrilintide, CagriSema vs Semaglutide, CagriSema vs Tirzepatide, 5-Amino-1MQ vs Semaglutide, AOD-9604 vs Fragment 176-191, HGH vs Tesamorelin, MOTS-c vs SLU-PP-332, MOTS-c vs Humanin, Cagrilintide vs Pramlintide, Cagrilintide vs Eloralintide, Cagrilintide vs Petrelintide, Eloralintide vs Petrelintide, CagriSema vs Amycretin, Semaglutide vs Amycretin, Tirzepatide vs Eloralintide, Semaglutide vs Petrelintide, Tirzepatide vs VK2735, Retatrutide vs VK2735, Tirzepatide vs Enicepatide, Semaglutide vs Ecnoglutide, Semaglutide vs Efinopegdutide, Survodutide vs Efinopegdutide, Pemvidutide vs Efinopegdutide and Melanotan II vs Setmelanotide.

How we ranked them

Each compound is placed on the highest rung its evidence for this goal reaches. First come compounds the FDA has approved for a use related to the goal, and only where the library entry says so. Next come compounds studied in people for it (in one of our study pages, or in the trials a research note of the library entry rests on), then those with animal or lab studies only, and last those resting on community reports alone.

Within a rung, compounds are ordered by how many of our study pages in people cover the goal, then by the library’s overall research rating, then by the number of study pages of any kind. A compound is on this page only because its library entry lists a use for this goal, says so in its description, or one of our study pages is about it; the reason is printed with each one.

This is a ranking of evidence, not of results, and not advice on what anyone should take.

Track it in the app

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo